Arpana Sehgal, Pharm.D.

Arpana is the Senior Vice President, Medical Information at Aexelar Inc. Arpana brings over 25 years of pharmaceutical industry experience in medical information and pharmacovigilance, along with 12 years of clinical hospital pharmacy experience. Arpana transitioned from the hospital pharmacy to the pharmaceutical industry 25 years ago and has worked with several multinational companies. Currently, Arpana leads the oversight of medical information projects at Cincinnati Children’s Hospital.

Dr. Sehgal started her career as a medical services specialist at TAP Pharmaceuticals Inc. (Division of Abbott Labs.) where she was responsible for the dissemination of medical information and adverse event reporting for TAP’s marketed drug products (Prevacid®, Prevpac®, Lupron®, and Spectracef®). Thereafter, at Procter & Gamble Pharmaceuticals, she was responsible for post-marketing pharmacovigilance of marketed products (Actonel®, Asacol®, Macrobid®, Macrodantin®, Dantrium®, Didronel®). Following that, Arpana joined the medical communications group at Cephalon (now Teva) and Elan Pharmaceuticals. She supported medical communications and medical reviews of advertising and promotional materials for several post marketed products including Fentora®, Actiq® and Oral Transmucosal Fentanyl Citrate (OTFC®) at Cephalon and for Tysabri®, Prialt®, Azactam®, and Maxipime® at Elan. Arpana worked as an Associate Director, Medical Communications for the Global Medical Affairs organization at Shire Inc. and was responsible for leading the medical communication activities and launch initiatives for the company’s Vyvanse® and Intuniv® products.

Dr. Sehgal has led medical information initiatives including developing and maintaining standard medical response letters to health care providers, medical information reviews of advertising and promotional materials, support of product launches in the US and Europe, and development of scientific/medical information in corporate Press Releases. Additionally, she has managed assessed, processed, coded, and reported global adverse events for development compounds and marketed drug products.

Arpana completed a Bachelor of Pharmacy degree from the University of Toronto in Toronto, Canada, and a Pharm.D. from the University of Wisconsin in Madison, Wisconsin.